Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 1/20 | 0.55 |
| ▸ | CLK1 | P49759 | 2/20 | 0.50 |
| ▸ | CDK5 | Q00535 | 2/20 | 0.50 |
| ▸ | CDK5R1 | Q15078 | 2/20 | 0.50 |
| ▸ | PDPK1 | O15530 | 2/20 | 0.50 |
| ▸ | JAK2 | O60674 | 2/20 | 0.50 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.50 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.50 |
| ▸ | CDK1 | P06493 | 1/20 | 0.50 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.50 |
| ▸ | PRKACA | P17612 | 1/20 | 0.50 |
| ▸ | PRKACG | P22612 | 1/20 | 0.50 |
| ▸ | PRKACB | P22694 | 1/20 | 0.50 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.50 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.50 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.50 |
| ▸ | GSK3B | P49841 | 1/20 | 0.50 |
| ▸ | CSNK1G2 | P78368 | 1/20 | 0.50 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.50 |
| ▸ | CSNK1G1 | Q9HCP0 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30121389 | 1.00 | CYP2A6 (0.55) | CYP2A6CLK1CDK5CDK5R1PDPK1 | |
| SCHEMBL3631962 | 0.83 | GPR84 (0.58) | CLK1CDK5CDK5R1PDPK1JAK2 | |
| Hydrochloric Acid SCHEMBL23168012 | 0.82 | GPR84 (0.56) | CLK1CDK5CDK5R1PDPK1JAK2 | |
| SCHEMBL30019124 | 0.78 | CYP2A6 (0.58) | CYP2A6CLK1CDK5CDK5R1PDPK1 | |
| SCHEMBL20354748 | 0.75 | CYP2A6 (0.55) | CYP2A6CLK1CDK5CDK5R1PDPK1 | |
| SCHEMBL22128417 | 0.75 | CYP2A6 (0.55) | CYP2A6CLK1CDK5CDK5R1PDPK1 | |
| SCHEMBL21291503 | 0.75 | CYP2A6 (0.55) | CYP2A6CLK1CDK5CDK5R1PDPK1 | |
| SCHEMBL22777931 | 0.75 | CYP2A6 (0.55) | CYP2A6CLK1CDK5CDK5R1PDPK1 | |
| SCHEMBL2804219 | 0.75 | CYP2A6 (0.55) | CYP2A6CLK1CDK5CDK5R1PDPK1 | |
| SCHEMBL14454516 | 0.75 | HTR2A (0.56) | HTR2AIDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12421230-B2 | Tricyclic heteroaryl compounds useful as IRAK4 inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2025-09-23 | — | — | US | disclosed |
| CN-115335380-B | Tricyclic heteroaryl compounds useful as IRAK4 inhibitors | 百时美施贵宝公司 | 2024-08-02 | — | — | CN | disclosed |
| EP-4100408-B1 | TRICYCLIC HETEROARYL COMPOUNDS USEFUL AS IRAK4 INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2024-02-28 | — | — | EP | disclosed |
| EP-4100408-B1 | TRICYCLIC HETEROARYL COMPOUNDS USEFUL AS IRAK4 INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2024-02-28 | — | — | EP | disclosed |
| US-20230114683-A1 | TRICYCLIC HETEROARYL COMPOUNDS USEFUL AS IRAK4 INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2023-04-13 | — | — | US | disclosed |
| EP-4100408-A1 | TRICYCLIC HETEROARYL COMPOUNDS USEFUL AS IRAK4 INHIBITORS | Bristol-Myers Squibb Company (US) | 2022-12-14 | — | — | EP | disclosed |
| CN-115335380-A | Tricyclic heteroaryl compounds useful as IRAK4 inhibitors | 百时美施贵宝公司 | 2022-11-11 | — | — | CN | disclosed |
| WO-2021158498-A1 | TRICYCLIC HETEROARYL COMPOUNDS USEFUL AS IRAK4 INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-08-12 | — | — | WO | disclosed |
| WO-2021158498-A1 | TRICYCLIC HETEROARYL COMPOUNDS USEFUL AS IRAK4 INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-08-12 | — | — | WO | disclosed |
| US-20140378416-A1 | SILYL-CONTAINING HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES | MERCK SHARP & DOHME CORP. | 2014-12-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230114683-A1 | TRICYCLIC HETEROARYL COMPOUNDS USEFUL AS IRAK4 INHIBITORS | IRAK4, IRAK3, IRAK2 | CYP2A6 4227/4885CLK1 2401/4885CDK5 989/4885 |
| US-20140378416-A1 | SILYL-CONTAINING HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES | ZC3HAV1L, HBS1L, HAVCR2 | CYP2A6 460/4885CLK1 2016/4885CDK5 1552/4885 |
| US-12421230-B2 | Tricyclic heteroaryl compounds useful as IRAK4 inhibitors | IRAK4, IRAK3, IRAK2 | CYP2A6 4227/4885CLK1 2401/4885CDK5 989/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.